Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.

Journal Article (Journal Article)

Purpose

To determine the time to disease recurrence with long-acting injectable fluocinolone acetonide implant (FAi) for noninfectious intermediate, posterior, and panuveitis.

Methods

This was a retrospective study of patients with at least 12 months of follow-up who had completed a 2-year prospective, investigational new drug study with 0.18-mg FAi. Time to uveitis recurrence or cystoid macular edema (CME) occurrence was recorded.

Results

Twelve eyes from 12 participants (mean age 43 years, range 25-64 years) were included. Patients were followed for a mean of 34.2 months (range, 12.0-56.9 months) after completion of the prospective trial. Five eyes (42%) did not have a documented uveitis recurrence or CME occurrence. Five eyes (42%) had a uveitis recurrence with the mean time to recurrence 36.1 months (range, 22.8-61.1 months) after FAi implantation. Two eyes (16%) had CME alone, the mean time to occurrence 36.9 months (range 36.1-42.1 months). On Kaplan-Meier analysis, the estimated probability of remaining recurrence-free 36 months after FAi implantation was 0.67 (95% confidence interval, 0.34-0.86).

Conclusions

Data of study participants after completing a clinical trial suggest that the injectable FAi for noninfectious uveitis can provide control for 3 years on average. These long-term data support the use of FAi to control noninfectious uveitis.

Full Text

Duke Authors

Cited Authors

  • Cai, CX; Skalak, C; Keenan, RT; Grewal, DS; Jaffe, GJ

Published Date

  • May 2020

Published In

Volume / Issue

  • 258 / 5

Start / End Page

  • 1023 - 1030

PubMed ID

  • 32114654

Electronic International Standard Serial Number (EISSN)

  • 1435-702X

International Standard Serial Number (ISSN)

  • 0721-832X

Digital Object Identifier (DOI)

  • 10.1007/s00417-020-04614-x

Language

  • eng